JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pickering, R. W.
Right arrow Articles by Chen, J. Y. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pickering, R. W.
Right arrow Articles by Chen, J. Y. P.
Journal of Pharmacology And Experimental Therapeutics, Vol. 95, Issue 2, 122-130, 1949
Copyright © 1949 by American Society for Pharmacology and Experimental Therapeutics

THE PHARMACOLOGY OF beta-PIPERIDINOETHYL PHENYL- agr-THIENYLGLYCOLATE HCl

Raymond W. Pickering 1, Benedict E. Abreu 1, Richard C. Burnett 1, Warren C. Bostick 1, and James Y. P. Chen 2

1 Divisions of Pharmacology and Experimental Therapeutics and Pathology, University of California Medical School, San Francisco, California
2 National Institute of Health, Nanking, China

1. The cardiovascular effects of PPT are as follows: (a) In monkeys, it produces no changes in cardiac rate, rhythm or conduction in subcutaneous doses of 4 mgm./kgm. (b) In dogs, it effectively abolishes the depressor effect of acetylcholine, but in doses as high as 10 mgm./kgm., intravenously, it does not alter the cardiovascular response to histamine or pitressin. (c) In the normal human, doses ranging from 2.5 to 35 mgm. orally, did not produce any changes in blood pressure, cardiac rate, rhythm or conduction.

2. The gastro-enteric effects of PPT are: (a) In monkeys, doses varying from 0.4 to 8 mgm./kgm., subcutaneously, induced spasmolysis in the intact colon rendered hyperactive by morphine. (b) In dogs, doses ranging from 1.0 to 2.5 mgm./kgm., intravenously, induced spasmolysis of normally active and hyperactive ileum and jejunum. (c) In the normal human, 5 and 10 mgm. doses, sublingually, depressed normal gastric motility.

3. The uterine effects of PPT are: (a) No changes were observed after intravenous doses ranging from 1 to 10 mgm./kgm. in the intact, non-pregnant, rabbit uterus or in the intact rat uterus with subcutaneous doses of 0.5-8.0 mgm./kgm. (b) Increase in activity was noted when concentrations ranging from 5 x 10-4 to 5 x 10-2 mgm./cc. bathed the isolated strip of the non-pregnant guinea pig.

4. Chronic toxicity: Daily administration of PPT to rabbits in doses of 40 mgm./kgm., subcutaneously, until death (46-68 days) slightly diminished renal and hepatic functions and increased red and white cell counts. The latter effect may be correlated with a progressive anorexia, weight loss, and dehydration. No significant histopathologic changes were produced.

5. General effects of PPT in the human: In doses from 2.5 to 30 mgm., there were no measurable changes in a two-hour observation period on central nervous, cardiovascular or respiratory systems. One subject, of four receiving 35 mgm., experienced vertigo, dimming of vision and chills lasting 80 minutes.

Submitted on October 13, 1948






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1949 by the American Society for Pharmacology and Experimental Therapeutics.